Healthcare resource utilization and costs of rivaroxaban versus warfarin among non-valvular atrial fibrillation (NVAF) patients with obesity in a US population.
J Med Econ
; 24(1): 550-562, 2021.
Article
em En
| MEDLINE
| ID: mdl-33910464
ABSTRACT
AIM:
To assess the real-world healthcare resource utilization (HRU) and costs of patients with non-valvular atrial fibrillation (NVAF) and obesity newly initiated on rivaroxaban or warfarin in the US.METHODS:
This retrospective study used IQVIA PharMetrics Plus data (01/2010-09/2019) to evaluate patients (≥18 years) with NVAF and obesity (body mass index ≥30 kg/m2) initiated on rivaroxaban or warfarin (on or after 01/2013). Inverse probability of treatment weighting (IPTW) was used to adjust for confounding between cohorts. HRU and costs were assessed post-treatment initiation. Weighted cohorts were compared using Poisson regression models and cost differences, with 95% confidence intervals (CIs) and p values generated using non-parametric bootstrap procedures.RESULTS:
After IPTW, 10,555 and 5,080 patients were initiated on rivaroxaban and warfarin, respectively (mean age 59 years). At 12 months follow-up, the rivaroxaban cohort had lower all-cause HRU, including fewer hospitalizations (rate ratio [RR] 0.80, 95% CI 0.74, 0.87), emergency room visits (RR 0.89, 95% CI 0.83, 0.97), and outpatient visits (RR 0.72, 95% CI 0.69, 0.77; all p < .05). Medical costs were also reduced in the rivaroxaban cohort (mean difference -$6,759, 95% CI -$9,814, -$3,311) due to reduced hospitalization costs (mean difference -$5,967, 95% CI -$8,721, -$3,327), resulting in lower total all-cause healthcare costs compared to the warfarin cohort (mean difference -$4,579, 95% CI -$7,609, -$1,052; all p < .05). The rivaroxaban cohort also had lower NVAF-related HRU and medical costs driven by lower hospitalization at 12 months post-treatment initiation. HRU and cost reductions associated with rivaroxaban persisted up to 36 months of follow-up.LIMITATIONS:
Claims data may have contained inaccuracies and obesity was classified based on ICD diagnosis codes given that patient BMI values were not available.CONCLUSIONS:
Rivaroxaban was associated with reduced HRU and costs compared to warfarin among NVAF patients with obesity in a real-world US setting.Palavras-chave
Texto completo:
1
Temas:
ECOS
/
Financiamentos_gastos
Bases de dados:
MEDLINE
Assunto principal:
Fibrilação Atrial
/
Acidente Vascular Cerebral
Tipo de estudo:
Health_economic_evaluation
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Aspecto:
Implementation_research
Limite:
Humans
/
Middle aged
Idioma:
En
Revista:
J Med Econ
Assunto da revista:
SERVICOS DE SAUDE
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Estados Unidos